A Better Way for Patients With T1D
The company provides education and advocacy resources for patients and caregivers with chronic diseases.

Sernova Biotherapeutics is a clinical-stage regenerative medicine company developing Cell Pouch, a cell-based bio-hybrid organ platform for type 1 diabetes.
sernova.comCrawled Nov 9, 2026
The company provides education and advocacy resources for patients and caregivers with chronic diseases.
See our suite of therapies for T1D, hypothyroidism, and hemophilia A, built with our bio-hybrid organ platform.
The page explains Type 1 diabetes as an autoimmune disorder requiring improved therapeutic solutions.
The Cell Pouch is a bio-hybrid approach to restoring function in chronic diseases.
The page provides access to presentations and publications about Sernova’s bio-hybrid organ.
Access the latest media and press releases about Sernova.
Sernova reported 2018 annual meeting results and appointed a new Chief Financial Officer in May 2018.
Sernova began a U.S. Phase I/II Cell Pouch clinical trial for diabetes in May 2018 with a prominent clinical investigator.
Sernova participated in the Biotech Showcase 2018 Healthcare Partnering Conference on January 5, 2018.
Sernova announced a Cell Pouch regenerative medicine clinical trial for Type 1 diabetes patients in February 2018.
The company develops therapeutic solutions for patients with chronic diseases.
David Paterson manages strategic industry relationships at Colorado State University and previously led business development at Impax Laboratories.
Dr. Bernd Muehlenweg has over 20 years of experience in business and corporate development, alliance management, and founding biotechnology start-ups.
Dr. Steven Sangha has over 25 years of experience in investment banking, business development, and asset management, including public company governance and finance.
James T. Parsons previously served as Chief Financial Officer of Trillium Therapeutics and has experience in life sciences strategy and finance.
Marylyn Rigby has 20 years of experience in pharmaceutical, biotechnology, and medical technology business development and executive leadership.
Tanya Lewis served as Chief Development Operations Officer at Replimune Group and held regulatory leadership roles at Karyopharm Therapeutics.
The page invites inquiries about Sernova’s Cell Pouch technology.
We’re advancing durable regenerative therapeutic solutions that correct the underlying cause of T1D and other chronic diseases.
The privacy policy was last updated on July 6, 2018, alongside the legal notice and terms of use.
Sernova’s website terms outline user responsibilities and legal agreements.
Seraxis and Sernova appoint **Dr. Patricia Beaston**, a former FDA medical officer, as **Chief Medical Officer (CMO)** for Seraxis and the merged entity **BetaNova Biotherapeutics**. Beaston’s expertise spans **24 years of FDA leadership** in **islet cell transplantation, cell and gene therapies, and type 1 diabetes**. The move consolidates medical oversight for the combined biotherapeutics operations post-merger.
Sernova Biotherapeutics executives Jonathan Rigby and Will Rust, Ph.D., will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference. They will discuss the proposed merger to create BetaNova Biotherapeutics and highlight advancements in their type 1 diabetes cell-replacement therapy platform. The platform aims to provide a differentiated approach to treating the chronic condition.
Sernova Biotherapeutics and Seraxis will present merger details to form **BetaNova Biotherapeutics**, positioning it as a leader in **Type 1 diabetes cell therapy**. The companies aim to combine expertise in bioengineered cell solutions. The announcement occurs during the **H.C. Wainwright 28th Annual Global Investor Conference**.
Sernova Biotherapeutics secures FDA orphan drug designation for its autologous islet transplantation (AIT) therapy, targeting diabetes prevention in patients undergoing total pancreatectomy. The company develops a Cell Pouch Bio-hybrid Organ system aimed at providing a functional cure for type 1 diabetes. This designation supports accelerated development and potential approval for treating rare conditions.
Sernova Biotherapeutics secures unanimous shareholder approval at its 2026 Annual General Meeting. The regenerative medicine company, developing a Cell Pouch Bio-hybrid Organ for type 1 diabetes treatment, holds its meeting on April 8, 2026. All proposed resolutions receive affirmative votes, reinforcing shareholder confidence in its diabetes cure pipeline.